jnj-61393215 jnj-61393215 jnj-61393215 is an orexin antagonist medication which is under development for the treatment of depression and anxiety disorders. it is an orally active compound and acts as a selective antagonist of the orexin ox1 receptor (1-sora). preliminary clinical findings suggest that jnj-61393215 may have anti-panic effects in humans. as of november 2021, jnj-61393215 is in phase 2 clinical trials for the treatment of major depressive disorder and is in the preclinical stage of development for treatment of panic disorder, while no further development has been reported for treatment of other anxiety disorders. the drug was originated and developed by janssen pharmaceuticals. jnj-61393215clinical dataother namesjnj-3215routes ofadministrationoraldrug classorexin receptor antagonistidentifiers iupac name oxy-2-azabicycloheptan-2-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone cas number1637681-55-0pubchem cid139030979chemspider76117730chemblchembl4776719chemical and physical dataformulac23h18f4n4o2molar mass458.417 g·mol−13d model (jsmol)interactive image smiles c1(2c(n1c(=o)c3=c(c(=cc=c3)f)c4=nc=cc=n4)(c2)oc5=nc=c(c=c5)c(f)(f)f) inchi inchi=1s/c23h18f4n4o2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18h,9-10,12h2/t13-,17+,18-/m1/s1/i12d2key:hukwiaxqbohzix-usknzqbosa-n